Inverted follicular keratosis

Summary

Inverted follicular keratosis (MONDO:0006563) is a disease. A subtype of seborrheic keratosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	inverted follicular keratosis
Mondo ID	MONDO:0006563
EFO	EFO:1000717
DOID	DOID:6945
ICD-11	2109084329
NCIT	C9007
SNOMED CT	394728005
UMLS	C0334019
MedGen	87190
Is cancer (heuristic)	no

Also known as: inverted follicular keratosis

Disease family

This is a subtype of seborrheic keratosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › keratosis › seborrheic keratosis › inverted follicular keratosis

Related subtypes (4): inflamed seborrheic keratosis, melanoacanthoma, vulvar seborrheic keratosis, eyelid seborrheic keratosis

Subtypes (1): vulvar inverted follicular keratosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.